eyeforpharma Barcelona 2016 conference

eyeforpharma 15 - 17 March 2016, Barcelona, Spain.
eyeforpharma Barcelona will set the vision for your 2020 plans. With 120% attendee growth you can join 1000+ industry leaders in commercial excellence, patient engagement and innovation at the unmissable pharma-stakeholder summit. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice.

The conference will bring together all key stakeholders, so you can collaborate and identify solutions in order to:

  • Gain Real Customer Insight. Reinvent your understanding of customer experience with a holistic multichannel solution
  • Deliver Outcomes. Enhance patient experience by partnering with external stakeholders and facilitating internal cross functionality
  • Sell Value. Engage the busier, more informed customer with impactful face-to-face, remote and digital communication
  • Develop a New Corporate Culture. Pioneer a progressive internal mind-set promoting collaboration, communication and trust

Why Attend?
90+ industry leading speakers including C-Suite, VP and Director level experts to share their experiences so you can make healthier corporate decisions. 2016 speakers include:

Keynotes

  • David Epstein, Novartis, Division Head and CEO Pharmaceuticals
  • Dominique Limet, ViiV, Healthcare
  • Jane Griffiths, Janssen, Company Group Chairman, Europe, Middle East & Africa
  • Gitte Aabo, LEO Pharma, CEO
  • Eduardo Javier Sanchiz Yrazu, Almirall, CEO
  • Murray Stewart, GSK, Chief Medical Officer
  • Tim Kneen, Merck, Executive President, Europe & Canada
  • David Loew, Sanofi Pasteur, COO
  • Andrew Hotchkiss, Eli Lilly and Company, President Europe and Canada
  • Jason DeGoes, Teva, SVP Patient Solutions

Patient Experience

  • Kasper Jerlang, LEO Pharma, Head - Global Patient Communications
  • Sanja Njegic, Novartis, Director Patient Relations, Europe
  • Henrik Finnern, Boehringer Ingelheim, Chief Patient Office
  • Anne Beal, Sanofi, Chief Patient Officer
  • Paul Robinson, MSD, Executive Director Scientific Medical and Patient Perspective

Commercial Excellence

  • Andreas Wandelt, Pfizer, Vice President, Global Sales and Marketing Services
  • Heléna Bargiel, LEO Pharma, Head of Global Field Force Excellence
  • Etienne Tichit, Novo Nordisk, Vice President, Commercial Excellence
  • Bharat Tewarie, UCB, EVP & Chief Marketing Officer
  • Chris-Carol Bremer, Grunenthal, SVP & Head of Marketing

See the complete speaker line-up here.

Don't miss Barcelona 2016, Europe’s premier pharmaceutical summit in commercial excellence, patient engagement and innovation!

Save €100 using World Pharma News unique code wpn100

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with...